After Acquisition, Tampa Biotech Firm Looks Toward COVID-19 Vaccine
Serendipity is the word Alan Joslyn uses to describe the meeting and eventual acquisition of a Gainesville-based biotech firm.
“It’s not every day all of a sudden a private company falls in your lap that’s working in COVID-19,” said Alan Joslyn, CEO of UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis. “We thought, ‘Wow, is this for real?’”
The pair met through their lawyer, based in Tampa, and in just two weeks a deal was made: Oragenics would acquire UF Innovate | The Hub resident client Noachis Terra Inc., a new biotechnology company that will focus its efforts on the development of a vaccine for COVID-19, and with it, a National Institute of Health license for its work on a coronavirus vaccine.
Learn more about After Acquisition, Tampa Biotech Firm Looks Toward COVID-19 Vaccine.Related news Oragenics Acquires Noachis Terra Inc., to Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein.”